@Biocartis_

PRESS RELEASE: Biocartis launches CE-marked IVD NRAS test for colorectal cancer

Mechelen, Belgium, 23 May 2017 - Biocartis Group NV (‘Biocartis’ or the ‘Company’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the launch of the Idylla™ NRAS Mutation Test. This newly launched CE-marked IVD test, alongside Biocartis’ existing Idylla™ NRAS-BRAF Mutation Test (CE-IVD), will now allow for more flexibility in geographies where BRAF testing for metastatic colorectal cancer (mCRC) patients is not reimbursed.

read more

PRESS RELEASE: Study demonstrating high performance of Idylla™ liquid biopsy RAS tests to be presented at ASCO Annual Meeting

Mechelen, Belgium, 18 May 2017 - Biocartis Group NV (‘Biocartis’ or the ‘Company’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of a study abstract1 demonstrating the high performance of Biocartis’ recently launched Idylla™ ctRAS liquid biopsy assays, which will be presented at the renowned ASCO Annual Meeting of the American Society of Clinical Oncology between June 2-6 in Chicago, US. The ASCO Annual Meeting is attended by more than 30,000 oncology professionals from all over the world.

read more